## REMARKS

The specification has been amended to correct spelling.

Applicants wish to point out that although in the Amendments to the Specification of the Amendment and Reply filed on July 1, 2005 the replaced paragraph was indicated as starting on page 14, line 12 of the specification filed on April 12, 2001, the paragraph text provided in the Amendment and Reply in fact starts on page 14, line 3.

Claims 72-73 have been added; these claims include no new matter. Paclitaxel as a therapeutic agent is discussed, for example, at the following points in the specification filed on April 12, 2001: page 14, lines 3-4 and 15-16; page 15, lines 11-13; page 17, lines 1-5; page 18, lines 4 and 9-10; page 19, lines 3-8; and page 21, lines 2-3, 7-9, and 14-27.

Claim 74 has been added; this claim includes no new matter. The heparin compounds are discussed, for example, at the following points in the specification filed: page 14, lines 11-13 ("heparin sodium, heparin complexed with quaternary ammonium compounds such as benzalkonium chloride, stearalkonium chloride, or tridodecylmethylammonium chloride"); and page 19, lines 12-14 (Table IV) ("benzalkonium heparinate").

Applicants wish to point out that although in the Amendments to the Claims of the Amendment and Reply filed on July 1, 2005 claim 50 was indicated as "previously presented", claim 50 in fact was "currently amended".

If the examiner believes, for any reason, that personal communication will expedite prosecution of this application, the examiner is hereby invited to telephone the undersigned at the number provided.

Appl. No. 09/834,307 Supplemental Amendment dated July 20, 2005 Following Office Action of January 6, 2005

A Notice of Allowance for all of the pending claims 23-74 is respectfully requested.

Respectfully submitted,

Date: July 20, 2005

Michael A. Gollin

Registration No. 31,957

VENABLE LLP

P.O. Box 34385

Washington, D.C. 20043-9998

Telephone: (202) 344-4000

Direct Dial: (202) 344-4072

Telefax: (202) 344-8300

DC2/665088v1